Rich nations have been gatekeeping Ozempic-like weight-loss drugs. WHO wants it to end

WHO supports GLP-1 medications for weight loss but urges lower prices and increased production for global access. New guidelines recommend GLP-1 drugs like Wegovy and Ozempic alongside diet, exercise, and medical supervision, excluding pregnant women. WHO calls for tiered pricing and voluntary licensing to prevent access gaps in lower-income regions.